2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure …

JW McEvoy, CP McCarthy, RM Bruno… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Acute aortic dissection

T Carrel, TM Sundt, Y von Kodolitsch, M Czerny - The Lancet, 2023 - thelancet.com
Although substantial progress has been made in the prevention, diagnosis, and treatment of
acute aortic dissection, it remains a complex cardiovascular event, with a high immediate …

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …

G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic …

L Mazzolai, G Teixido-Tura, S Lanzi, V Boc… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

[PDF][PDF] 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …

M Brunström, M Burnier… - Journal of …, 2023 - docred-strapi-cms-prod.s3.sa-east-1 …
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

J Tamargo, S Agewall, C Borghi… - European Heart …, 2023 - academic.oup.com
Cardiovascular diseases (CVD) remain the leading cause of death worldwide, and
pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to …

Endothelial HDAC1-ZEB2-NuRD complex drives aortic aneurysm and dissection through regulation of protein S-sulfhydration

S Luo, C Kong, S Zhao, X Tang, Y Wang, X Zhou, R Li… - Circulation, 2023 - Am Heart Assoc
Background: Aortic aneurysm and aortic dissection (AAD) are life-threatening vascular
diseases, with endothelium being the primary target for AAD treatment. Protein S …

[HTML][HTML] A review of polypills for the prevention of atherosclerotic cardiovascular disease

F Agnello, S Finocchiaro, C Laudani, M Legnazzi… - American heart …, 2023 - Elsevier
Atherosclerotic cardiovascular disease (ASCVD) is a prevalent chronic condition managed
through pharmacotherapy targeting modifiable risk factors. However, ASCVD patients often …

Endothelial dysfunction in Marfan syndrome mice is restored by resveratrol

A Mieremet, M van der Stoel, S Li, E Coskun… - Scientific reports, 2022 - nature.com
Patients with Marfan syndrome (MFS) develop thoracic aortic aneurysms as the aorta
presents excessive elastin breaks, fibrosis, and vascular smooth muscle cell (vSMC) death …

The aortic team model and collaborative decision pathways for the management of complex aortic disease: clinical practice update from the Canadian Cardiovascular …

RS McClure, TF Lindsay, M Keir, JP Bayne… - Canadian Journal of …, 2023 - Elsevier
Disease of the aortic arch, descending thoracic, or thoracoabdominal aorta necessitates
dedicated expertise across medical, endovascular, and surgical specialties. Cardiologists …